AZD3759 clinical trials
Also written AZD3759.
How each study uses AZD3759 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AZD3759 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AZD3759
- 4
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Alpha Biopharma (Jiangsu) Co., Ltd. (2) · LYZZ Alpha Holding Ltd (1) · AstraZeneca (1) · Guangdong Association of Clinical Trials (1)
Often tested with
Tested in the same studies.
Osimertinib (1) · Abivertinib (1) · Crizotinib (1) · Ensartinib (1) · Tucidinostat (1) · Shr-1258 dimaleate (1) · Pirotinib (1) · Nimotuzumab (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses AZD3759 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Zorifertinib With Osimertinib for NSCLC With Meningeal ProgressionRecruitingPhase 1Alpha Biopharma (Jiangsu) Co., Ltd.NCT07361705Written as Zorifertinib and Osimertinib Combination Therapy
- First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesCompletedPhase 2/3Alpha Biopharma (Jiangsu) Co., Ltd.NCT03653546Written as AZD3759
- Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownPhase 2Guangdong Association of Clinical TrialsNCT03574402Written as AZD3759
- Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759CompletedPhase 1/2LYZZ Alpha Holding LtdNCT03360929Written as AZD3759
- Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerCompletedPhase 1AstraZenecaNCT02228369Written as AZD3759
Codes
What other systems call AZD3759 · ClinicalTrials.gg INT000392
- MeSH (NLM) C000604577AZD3759One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604577 | AZD3759 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.